Research programme: epidermal growth factor receptor antagonists - Beta Pharma

Drug Profile

Research programme: epidermal growth factor receptor antagonists - Beta Pharma

Alternative Names: BPI 7711; BPI-0403; BPI-4039

Latest Information Update: 12 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Beta Pharma
  • Class Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-small cell lung cancer
  • Discontinued Pancreatic cancer

Most Recent Events

  • 10 Nov 2016 Pharmacodynamics and animal toxicology data from preclinical trials released by Beta Pharma before November 2014
  • 09 Nov 2016 Discontinued - Preclinical for Pancreatic cancer in USA (unspecified route)
  • 30 Sep 2016 Beta Pharma files a Clinical Trial Application with the FDA in China for conducting a clinical trial of BPI 7711 for Non-small cell lung cancer before September 2016 (Beta Pharma website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top